Pain is a serious and undertreated problem in the United States. Opioids are useful in treating patients with moderate-to-severe chronic noncancer pain who have not responded adequately to other pain management therapies. However, abuse of prescription opioids has escalated along with their increased legitimate use in pain management. Because of the potential for opioid abuse, patients and clinicians may be reluctant to initiate opioid therapy for pain relief. Hence, there is a need for effective pain relief while minimizing the risk of aberrant drug-related behaviors.
At the conclusion of this activity, participants should be better able to:
Accreditor Statement of Disclosure and Independence:
It is the policy of Primary Care Network (PCN) to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest and Disclosure Policies that are designed to ensure that PCN sponsored educational activities are fair balanced, independent, evidence-based and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
Review Committee Disclosure:
In accordance with PCN policy, all content is reviewed by external independent peer reviewers for balance, objectivity, and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Dr. McCarberg is on the speaker’s bureau for Abbott Laboratories, Cephalon, Eli Lilly, Forest Laboratories, Johnson & Johnson, Merck & Co., Ortho-McNeil, Pfizer, and Wyeth.
Dr. Gregory has nothing to disclose.
Disclosure of Unlabeled Use:
During this activity, author(s) may discuss an unlabeled use or an investigational use not approved for a commercial product. Each author is required to disclose this information to the participants when referring to an unlabeled or investigational use.
It is hoped that information in this activity will be useful in the management of your patients. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, review of any applicable manufacturers' product information, and comparison with recommendations of recognized authorities.
The information in this activity is provided to medical professionals for information purposes only. It is NOT to be disseminated to patients or for any other purpose. In particular, no information contained within this program is intended to be used for medical diagnosis or treatment.
The authors are exclusively responsible for the respective content. Accordingly, no responsibility is assumed by the contributing faculty, educational grant providers, and Primary Care Network and its affiliates associated with this activity for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise; or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without medically appropriate (1) evaluation of (a) their patients' conditions and (b) indications and possible contraindications, warnings, and adverse effects or dangers in use; (2) review of any applicable manufacturers' prescribing and other product information; (3) comparison with recommendations of recognized authorities; and (4) independent verification of diagnostic methods, therapeutic methods, results of research, and measurement of medical doses.
Content for this activity developed by Integrity Continuing Education
Sponsored by Primary Care Network
Supported by an educational grant from King Pharmaceuticals, Inc.
Produced by Primary Issues
If you have any questions relating to the accreditation of this activity, please contact Primary Care Network.
If you have any questions relating to your certificate or technical issues for this activity, please contact Chris Bubeck.
Phone: (646) 638-6091
AMA PRA Category 1 Credit(s)TM
Primary Care Network is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Primary Care Network designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To receive credit for this activity, you must read the CME information (including learning objectives and disclosures) and the article, and obtain a score of 70% or better on the posttest. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
Copyright © 2010. Primary Issues. All rights reserved.